Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes.
Schwaab J, Naumann N, Luebke J, Jawhar M, Somervaille TCP, Williams MS, Frewin R, Jost PJ, Lichtenegger FS, La Rosée P, Storch N, Haferlach T, Horny HP, Fabarius A, Haferlach C, Burchert A, Hofmann WK, Cross NCP, Hochhaus A, Reiter A, Metzgeroth G.
Schwaab J, et al. Among authors: storch n.
Am J Hematol. 2020 Jul;95(7):824-833. doi: 10.1002/ajh.25825. Epub 2020 Apr 28.
Am J Hematol. 2020.
PMID: 32279331
Free article.
Clinical Trial.